Technical Analysis for SCLP - Scancell Holdings Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.71% | |
| Inside Day | Range Contraction | 0.71% | |
| Lower Bollinger Band Touch | Weakness | 0.71% | |
| Oversold Stochastic | Weakness | 0.71% | |
| Lower Bollinger Band Walk | Weakness | 0.71% | |
| Below Lower BB | Weakness | 0.71% | |
| Down 3 Days in a Row | Weakness | 0.71% | |
| Lower Bollinger Band Touch | Weakness | 0.71% | |
| Oversold Stochastic | Weakness | 0.71% | |
| Spinning Top | Other | -0.33% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 1 hour ago |
| Possible NR7 | about 2 hours ago |
| Down 1% | about 6 hours ago |
| Rose Above Previous Day's High | about 6 hours ago |
| Fell Below Lower Bollinger Band | about 6 hours ago |
Get a Trading Sidekick!
Scancell Holdings Plc Description
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Medicine Cancer Pipe Branches Of Biology Medical Specialties Clinic Biopharmaceutical Therapy Clinical Trial Monoclonal Antibodies Antibodies Vaccine Antibody Immunology Tumor Immune System Therapies Lung Cancer Treatment Of Cancer Immunotherapies Melanoma Immunotherapy Cancer Therapeutics Monoclonal Antibody Treatment Of Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.3 |
| 52 Week Low | 7.588 |
| Average Volume | 415,916 |
| 200-Day Moving Average | 11.51 |
| 50-Day Moving Average | 10.62 |
| 20-Day Moving Average | 10.11 |
| 10-Day Moving Average | 9.90 |
| Average True Range | 0.50 |
| RSI (14) | 30.56 |
| ADX | 14.03 |
| +DI | 13.86 |
| -DI | 15.50 |
| Chandelier Exit (Long, 3 ATRs) | 9.60 |
| Chandelier Exit (Short, 3 ATRs) | 10.80 |
| Upper Bollinger Bands | 10.69 |
| Lower Bollinger Band | 9.53 |
| Percent B (%b) | 0.01 |
| BandWidth | 11.45 |
| MACD Line | -0.25 |
| MACD Signal Line | -0.21 |
| MACD Histogram | -0.0447 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.93 | ||||
| Resistance 3 (R3) | 9.90 | 9.74 | 9.87 | ||
| Resistance 2 (R2) | 9.74 | 9.64 | 9.76 | 9.85 | |
| Resistance 1 (R1) | 9.65 | 9.58 | 9.68 | 9.68 | 9.83 |
| Pivot Point | 9.49 | 9.49 | 9.50 | 9.50 | 9.49 |
| Support 1 (S1) | 9.39 | 9.39 | 9.42 | 9.42 | 9.27 |
| Support 2 (S2) | 9.23 | 9.33 | 9.25 | 9.25 | |
| Support 3 (S3) | 9.14 | 9.23 | 9.23 | ||
| Support 4 (S4) | 9.17 |
